Carbamazepine is an anticonvulsant and specific analgesic for trigeminal neuralgia. It may work by inhibiting polysynaptic responses and blocking posttetanic potentiation, and can significantly reduce or eliminate pain caused by stimulation of the infraorbital nerve in rats and cats, and reduce thalamic potentials, medulla oblongata, and polysynaptic reflexes in cats, including the glossom-mandibular reflex.

Anticonvulsant effects have been demonstrated in some animal models of epilepsy; although the epoxide is inferred to have clinical activity, the impact of its activity on the safety and efficacy of carbamazepine is unclear.

Carbamazepine is an anticonvulsant and specific analgesic for trigeminal neuralgia. It may work by inhibiting polysynaptic responses and blocking posttetanic potentiation, and can significantly reduce or eliminate pain caused by stimulation of the infraorbital nerve in rats and cats, and reduce thalamic potentials, medulla oblongata, and polysynaptic reflexes in cats, including the glossom-mandibular reflex.

Anticonvulsant effects have been demonstrated in some animal models of epilepsy; although the epoxide is inferred to have clinical activity, the impact of its activity on the safety and efficacy of carbamazepine is unclear.

Anticonvulsant effects have been demonstrated in some animal models of epilepsy; although the epoxide is inferred to have clinical activity, the impact of its activity on the safety and efficacy of carbamazepine is unclear.

Carbamazepine is an anticonvulsant and specific analgesic for trigeminal neuralgia, which may work by inhibiting polysynaptic responses and blocking posttetanic potentiation; it can significantly reduce or eliminate the pain caused by stimulation of the infraorbital nerve in rats and cats, and reduce the thalamic potential, medullary and polysynaptic reflexes in cats, including the glossom-mandibular reflex.

Anticonvulsant effects have been demonstrated in some animal models of epilepsy; although the epoxide is inferred to have clinical activity, the impact of its activity on the safety and efficacy of carbamazepine is unclear.

Anticonvulsants and specific analgesics for trigeminal neuralgia may work by inhibiting polysynaptic responses and blocking posttetanic potentiation; they can significantly reduce or eliminate the pain caused by stimulation of the infraorbital nerve in rats and cats, and reduce the thalamic potential, medullary and polysynaptic reflexes in cats, including the glossom-mandibular reflex.

Anticonvulsant activity has been demonstrated in some animal models of epilepsy; although this is inferred to be clinically active, its impact on the safety and efficacy of carbamazepine is unclear.

Carbamazepine is an anticonvulsant and specific analgesic for trigeminal neuralgia, which may work by inhibiting polysynaptic responses and blocking posttetanic potentiation; it can significantly reduce or eliminate pain caused by stimulation of the infraorbital nerve in rats and cats, and reduce thalamic potentials, medulla oblongata and polysynaptic reflexes in cats, including the glossomaxillary reflex. Its mechanism of action is still unclear.

The major metabolite of carbamazepine shows anticonvulsant effects in some animal models of epilepsy. Although the epoxide is presumed to have clinical activity, the impact of its activity on the safety and efficacy of carbamazepine is unclear.